Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

AIMS: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patie...

Full description

Saved in:
Bibliographic Details
Published in:Int J Clin Pract
Main Authors: Wilding, J P H, Charpentier, G, Hollander, P, González-Gálvez, G, Mathieu, C, Vercruysse, F, Usiskin, K, Law, G, Black, S, Canovatchel, W, Meininger, G
Format: Artigo
Language:Inglês
Published: BlackWell Publishing Ltd 2013
Subjects:
Endocrinology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282288/
https://ncbi.nlm.nih.gov/pubmed/24118688
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12322
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items